Cannell & Co’s Labcorp LH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $77.5M | Buy |
340,869
+130,449
| +62% | +$27.4M | 2.46% | 8 |
|
|
2023
Q3 | $42.3M | Buy |
210,420
+56,628
| +37% | +$11.9M | 1.45% | 20 |
|
|
2023
Q2 | $31.9M | Buy |
153,792
+5,330
| +4% | +$1.03M | 1.06% | 29 |
|
|
2023
Q1 | $29.3M | Buy |
148,462
+9,965
| +7% | +$2.05M | 1.05% | 30 |
|
|
2022
Q4 | $28M | Buy |
138,497
+1,818
| +1% | +$355K | 1.01% | 33 |
|
|
2022
Q3 | $24M | Sell |
136,679
-580
| -0.4% | -$119K | 0.92% | 38 |
|
|
2022
Q2 | $27.6M | Sell |
137,259
-1,306
| -0.9% | -$278K | 0.99% | 33 |
|
|
2022
Q1 | $31.4M | Sell |
138,565
-1,128
| -0.8% | -$265K | 0.94% | 34 |
|
|
2021
Q4 | $37.7M | Sell |
139,693
-4,592
| -3% | -$1.14M | 1.07% | 26 |
|
|
2021
Q3 | $34.9M | Sell |
144,285
-5,621
| -4% | -$1.42M | 1.07% | 27 |
|
|
2021
Q2 | $35.5M | Sell |
149,906
-8,073
| -5% | -$1.84M | 1.06% | 30 |
|
|
2021
Q1 | $34.6M | Sell |
157,979
-2,267
| -1% | -$455K | 1.09% | 28 |
|
|
2020
Q4 | $28M | Buy |
160,246
+6,369
| +4% | +$1.1M | 0.93% | 38 |
|
|
2020
Q3 | $24.9M | Sell |
153,877
-1,696
| -1% | -$269K | 0.91% | 39 |
|
|
2020
Q2 | $22.2M | Sell |
155,573
-482
| -0.3% | -$66.7K | 0.87% | 38 |
|
|
2020
Q1 | $16.9M | Sell |
156,055
-1,182
| -0.8% | -$170K | 0.81% | 41 |
|
|
2019
Q4 | $22.9M | Sell |
157,237
-40
| -0% | -$5.78K | 0.81% | 42 |
|
|
2019
Q3 | $22.7M | Sell |
157,277
-30,672
| -16% | -$4.48M | 0.86% | 39 |
|
|
2019
Q2 | $27.9M | Buy |
187,949
+33,380
| +22% | +$4.66M | 1.06% | 33 |
|
|
2019
Q1 | $20.3M | Sell |
154,569
-2,733
| -2% | -$337K | 0.79% | 46 |
|
|
2018
Q4 | $17.1M | Buy |
157,302
+1,374
| +0.9% | +$184K | 0.75% | 44 |
|
|
2018
Q3 | $23.3M | Sell |
155,928
-1,735
| -1% | -$264K | 0.82% | 39 |
|
|
2018
Q2 | $24.3M | Sell |
157,663
-2,299
| -1% | -$347K | 0.91% | 38 |
|
|
2018
Q1 | $22.2M | Sell |
159,962
-4,021
| -2% | -$591K | 0.84% | 45 |
|
|
2017
Q4 | $22.5M | Sell |
163,983
-1,513
| -0.9% | -$200K | 0.77% | 45 |
|
|
2017
Q3 | $21.5M | Sell |
165,496
-4,115
| -2% | -$549K | 0.74% | 43 |
|
|
2017
Q2 | $22.5M | Buy |
169,611
+3,591
| +2% | +$440K | 0.77% | 44 |
|
|
2017
Q1 | $20.5M | Buy |
166,020
+4,027
| +2% | +$477K | 0.72% | 48 |
|
|
2016
Q4 | $17.9M | Buy |
161,993
+3,321
| +2% | +$369K | 0.65% | 49 |
|
|
2016
Q3 | $18.7M | Sell |
158,672
-727
| -0.5% | -$85.7K | 0.68% | 49 |
|
|
2016
Q2 | $17.8M | Sell |
159,399
-2,212
| -1% | -$238K | 0.65% | 50 |
|
|
2016
Q1 | $16.3M | Sell |
161,611
-640
| -0.4% | -$61.4K | 0.58% | 51 |
|
|
2015
Q4 | $17.2M | Sell |
162,251
-3,027
| -2% | -$312K | 0.56% | 53 |
|
|
2015
Q3 | $15.4M | Sell |
165,278
-334
| -0.2% | -$34.6K | 0.5% | 57 |
|
|
2015
Q2 | $17.2M | Sell |
165,612
-104
| -0.1% | -$10.8K | 0.49% | 54 |
|
|
2015
Q1 | $18M | Sell |
165,716
-615
| -0.4% | -$63.2K | 0.52% | 55 |
|
|
2014
Q4 | $15.4M | Sell |
166,331
-4,668
| -3% | -$412K | 0.46% | 59 |
|
|
2014
Q3 | $14.9M | Sell |
170,999
-1,804
| -1% | -$163K | 0.47% | 58 |
|
|
2014
Q2 | $15.2M | Buy |
172,803
+931
| +0.5% | +$80.6K | 0.47% | 55 |
|
|
2014
Q1 | $14.5M | Buy |
+171,872
| New | +$13.7M | 0.47% | 54 |
|
Other funds holding LH
Cannell & Co's LH Position: Q4 2023 in Review
Cannell & Co increased its Labcorp (LH) stake by 62% in Q4 2023, buying an estimated $27.4M and bringing the position to 340,869 shares worth $77.5M. The position accounts for 2.46% of the portfolio, ranked #8.
Cannell & Co first reported a position in LH in Q1 2014 and has held it in 40 quarters since. 956 funds tracked by Wall St. Rank hold LH as of Q4 2023.
- Cannell & Co held 340,869 shares of Labcorp worth $77.5M as of Q4 2023.
- Cannell & Co bought 130,449 Labcorp shares in Q4 2023, an estimated $27.4M.
- Labcorp made up 2.46% of Cannell & Co's portfolio in Q4 2023, its #8 holding.
- Cannell & Co first reported a position in Labcorp in Q1 2014 and has held it in 40 quarters since.
- 956 funds tracked by Wall St. Rank held Labcorp as of Q4 2023.
Based on Cannell & Co's 13F filing for Q4 2023, filed 5 Feb 2024.